Stomach Cancer Trial, Recruiting NCT03823144 Sponsor: Mayo Clinic Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT03823144
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People whose overall health and ability to carry out daily activities meets a certain minimum level (a score of 2 or less on a standard medical scale used in cancer care)
  • People who have a tumour that can be seen and measured, and that needs to be surgically removed in an operating room
  • People whose cancer is one of the following types: stomach (gastric), pancreatic, liver or bile duct (hepatobiliary), colorectal, sarcoma, brain, or breast cancer that may involve the lymph nodes under the arm — whether the tumour is the original (primary) cancer or one that has spread (metastatic)
  • People who understand the research nature of this study and are willing to sign a written consent form approved by an ethics committee
  • People who are able to have a skin prick test done before surgery (after signing the consent form) to check for any sensitivity to a substance called fluorescein, which is used in the trial

Who may not be able to join:

  • People with serious uncontrolled illnesses, such as an active infection, heart failure with symptoms, unstable chest pain, irregular heart rhythms, or significant mental health or social circumstances
  • People whose kidneys are not working well enough (a specific kidney function measurement called GFR is below 45)
  • People whose liver is not working well enough, based on standard scoring measures or abnormal liver blood test results
  • People who have a known allergy or previous reaction to fluorescein, or who test positive on the pre-operative skin prick test for fluorescein
  • People who are pregnant or breastfeeding (confirmed by a urine pregnancy test before surgery)
  • People who are unwilling or unable to follow the requirements of the study protocol
  • People who have any other condition that the study doctors consider makes participation unsuitable — for example, certain abnormal heart readings on an electrical heart tracing (ECG), or a condition that needs further heart investigations such as an echocardiogram or stress test
  • People for whom surgical removal of the tumour is not considered the appropriate standard treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Emmanuel M Gabriel, M.D., Ph.D., Mayo Clinic

Phone: 904-953-2523

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
28 February 2019
Est. completion
30 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

1. Tumor vessel identification (# tumor vessels visualized per high power field); 2. Tumor vessel density (# tumor vessels per square cm area observed); 3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake); 4. Tumor blood flow (velocity, mm/sec)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov